Safety & tolerability
Safety profile & toxicology
Turmimax® BIO safety has been evaluated through acute oral toxicology testing and monitored human clinical use - including a 12-week RDBPC study in 100 adults with mild-to-moderate knee osteoarthritis.
2,000 mg/kg
Acute oral dose - no mortality
84 days
Human clinical monitoring
0
Serious adverse events reported
Acute toxicology
No observable acute toxicity at 2,000 mg/kg
In the acute oral toxicity study summarised in the Turmimax® BIO dossier, the test material was administered at doses up to 2,000 mg/kg body weight. At the highest tested dose:
- No mortality observed
- No acute toxic symptoms reported
- No significant differences in body weight
- Normal physiological responses
- Food intake not significantly affected
Human tolerability
Well tolerated across 84 days
The clinical summary describes Turmimax® BIO as well tolerated, with minimal side effects and no serious adverse events reported during the 84-day study period. Safety was tracked through comprehensive clinical laboratory and vital-sign monitoring.
Systolic & diastolic blood pressure
Pulse, respiratory rate, body temperature
Complete blood count
Liver & renal function testing
Fasting blood glucose & lipid profile
Urine analysis
Adverse event & concomitant medication monitoring